Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd has filed a Writ Petition before the Hon'ble High Court of Gujarat at Ahmedabad challenging an order dated August 29, 2026, from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat. This order levied stamp duty and penalties totaling ₹59,50,00,000 (₹59.5 Crore) in respect of a Scheme of Arrangement (Demerger) sanctioned by the Hon'ble NCLT, Ahmedabad Bench. This filing is a continuation of a previous communication dated September 02, 2026, regarding the same matter.

Aarti Pharmalabs Ltd announced the reconstitution of its Nomination and Remuneration Committee, effective October 01, 2026. The Board of Directors approved the changes on September 30, 2026. The committee now comprises Smt. Jeenal Savla as Chairperson, Dr. Vinay Nayak and Shri Pradeep Thakur as Members (all Independent Directors), and Shri Rashesh Gogri as a Member (Executive Director). This move is in compliance with SEBI Listing Regulations.

Aarti Pharmalabs Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from October 1, 2026, until 48 hours after the declaration of the financial results for the quarter ending September 30, 2026. All designated and connected persons have been informed. The date of the board meeting to approve these results will be communicated separately.

Aarti Pharmalabs Ltd announced significant changes in its Directorate following its 7th Annual General Meeting (AGM) held on September 22, 2026. Shri Rajendra Gogri ceased to be a Non-Executive Non-Independent Director as he did not offer himself for re-appointment upon retirement by rotation. Concurrently, Smt. Hetal Gogri Gala was re-designated from Managing Director to Whole-time Director, and Shri Rashesh C. Gogri was appointed as the new Managing Director, both changes effective October 1, 2026. These changes were approved by the company's members based on the voting results submitted by the scrutinizer.

Gloire Trusteeship Services Pvt Ltd (Lotus Family Trust) and other promoters of Aarti Pharmalabs Limited have disclosed changes in their shareholding. The total promoter and promoter group holding has decreased from 42.88% to 39.66% as of September 21, 2026. This change is primarily due to a sale of shares by Gloire Trusteeship Services Pvt Ltd and a net sale by other promoters and promoter group entities, partially offset by minor acquisitions by other promoters.

Aarti Pharmalabs Limited has received an order from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat, levying a total of ₹59.5 Crores in stamp duty and penalties. This order pertains to the demerger scheme between Aarti Industries Limited and Aarti Pharmalabs Limited, sanctioned by the NCLT in September 2022. The company has been charged ₹25 Crores in stamp duty, ₹25 Crores as penalty for deficient duty, and an additional ₹9.5 Crores under the Gujarat Stamp Act. Aarti Pharmalabs believes it has strong grounds to challenge the order and is evaluating its legal options.

Aarti Pharmalabs Ltd has announced the resignation of Shri G.M. Naidu, Manufacturing/Sr. General Manager and Senior Management Personnel. His resignation, submitted via email on June 10, 2026, is effective from the closure of business hours on August 31, 2026. The company cited personal commitments as the reason for his departure. Shri Naidu expressed gratitude for his tenure and committed to ensuring a smooth transition. The company has provided the necessary disclosures as per SEBI regulations.

Aarti Pharmalabs Ltd has announced its 7th Annual General Meeting (AGM) scheduled for Tuesday, September 22, 2026, at 11:00 a.m. IST. The meeting will be conducted entirely through Video Conferencing (VC) / Other Audio Visual Means (OAVM), without physical presence. The Annual Report for the Financial Year 2025-26 and the Notice of the AGM are being disseminated electronically to shareholders whose email addresses are registered. For shareholders without registered emails, letters with web links to the Annual Report are being sent. The Annual Report, available on the company's website, details the company's performance, financial statements, and strategic initiatives, including investments in manufacturing, R&D, and CDMO growth.

Aarti Pharmalabs Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as per SEBI Listing Regulations. The report details the company's corporate identity, registered and corporate office addresses, financial year, and stock exchange listings. It outlines the business activities, primarily focused on manufacturing Pharmaceuticals and Nutraceuticals, contributing 100% to turnover, with specific product segments including APIs, Pharmaceutical Intermediates, New Chemical Entities, and Xanthine Derivatives. The company operates across 15 national locations and serves 25 states and 51 countries, with exports accounting for approximately 55.93% of its total turnover. The BRSR also highlights the company's proactive approach to obtaining Type 2 Moderate Assurance for its Sustainability Report and BRSR Core indicators.

Aarti Pharmalabs Ltd has filed its Annual Report for the Financial Year 2025-26, along with the Notice of its 7th Annual General Meeting (AGM). The AGM is scheduled for September 22, 2026, at 11:00 a.m. IST, and will be conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM) without physical presence. The report details the company's performance, financial statements, and strategic initiatives, including investments in manufacturing capacity, scientific capabilities, and technology, particularly focusing on growth in the CDMO segment. The Annual Report is available on the company's website.